



School of Public Health



Family Medicine Research Centre

# BEACH

**Bettering the Evaluation And Care of Health**

**Allopurinol**

**April 2005 – March 2006 (12 months weighted data)**

## Explanatory notes for Problem Report

### Background

This report represents a summary of the data collected from April 2005 until March 2006 inclusive. It provides information on the prescribing of allopurinol (ATC code 'M04AA').

Each year, BEACH collects data from around 1,000 GPs, who each records details about 100 consecutive consultations, thus providing an annual database of approximately 100,000 records.

### Summary of BEACH data

BEACH Year	Number of GPs Raw (weighted)	Number of encounters Raw (weighted)	Number of problems managed Raw (weighted)	Number of medications (prescribed, GP supplied, over the counter) Raw (weighted)	Number of prescribed medications Raw (weighted)
April 1998-March 1999	984 (969.0)	98,400 (96,900.9)	145,183 (140,823.7)	107,451 (106,320.0)	91,427 (90,709.9)
April 1999-March 2000	1047 (1048.6)	104,700 (104,856.3)	156,576 (153,857.1)	113,555 (115,431.5)	96,925 (98,371.8)
April 2000-March 2001	999 (993.1)	99,900 (99,307.3)	147,518 (143,528.3)	108,179 (107,399.6)	91,602 (91,647.2)
April 2001-March 2002	983 (969.7)	98,300 (96,972.9)	144,372 (139,091.8)	102,352 (101,349.9)	85,304 (85,332.1)
April 2002-March 2003	1008 (1009.9)	100,800 (100,987.0)	149,976 (146,335.7)	103,289 (104,813.3)	83,755 (85,161.4)
April 2003-March 2004	1000 (1000.0)	100,000 (98,876.7)	150,126 (144,674.0)	103,774 (103,210.1)	85,023 (85,073.4)
April 2004-March 2005	953 (954.0)	95,300 (94,385.8)	141,489 (137,329.9)	95,672 (95,816.3)	77,913 (78,711.1)
April 2005-March 2006	1017 (1017.3)	101,700 (101,993.0)	152,802 (149,087.9)	105,340 (106,492.6)	85,600 (87,543.6)
April 2006-March 2007	930 (930.0)	93,000 (91,804.7)	140,886 (136,333.2)	93,140 (93,193.5)	75,495 (76,430.4)
April 2007-March 2008	953 (953.1)	95,300 (95,897.7)	147,724 (145,078.0)	96,488 (98,439.3)	76,440 (79,051.3)
April 2008-March 2009	1011 (1011.1)	101,100 (96,687.7)	159,412 (149,462.2)	108,545 (102,737.1)	88,458 (83,509.4)
April 2009-March 2010	988 (988.4)	98,800 (101,349.0)	155,889 (155,372.6)	103,232 (108,000.6)	79,229 (84,539.5)
April 2010-March 2011	958	95,800	150,909	100,584	80,712

	(958.0)	(95,839.0)	(146,141.1)	(100,816.6)	(81,542.5)
April 2011-March 2012	(984.0)	98,400	154,963	103,320	82,574
	98,400	(99,030.0)	(152,285.5)	(106,007.5)	(85,980.4)
April 2012-March 2013	978	97,800	155,212	99,439	79,593
	(977.8)	(98,563.9)	(152,517.0)	(101,064.9)	(82,078.8)

The participating GPs are randomly selected from the HIC list of active GPs (those who provided more than 375 GP services in the previous quarter). The research instrument used for each consultation is a single page recording form. An example of the recording forms can be found in Appendix 1 of the BEACH annual report, General practice activity in Australia 2011–12 <[http://ses.library.usyd.edu.au/bitstream/2123/8675/4/9781743320198\\_ONLINE.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/4/9781743320198_ONLINE.pdf)>. The recording form contains the following variables:

- Date of encounter
- Medicare Benefits Schedule (MBS) item number (up to three)/form of payment/indirect encounters (e.g. telephone consults)
- Patient age and sex
- Patient status to practice (new or seen before)
- Health care card status of patient
- Patient post code and ethnic background
- Patient's reasons for encounter (up to three per encounter)
- Diagnoses/problems managed (up to four)
- Status of each problem to the patient (new/old)
- Whether problems are work related
- Medications prescribed (up to four per problem)
- Over the counter medications recommended
- Medications provided by the GP
- Name, strength and regimen of medication
- Number of repeats for medication
- Medication status - new or continued
- Other treatments (up to two per problem)

- Pathology tests ordered (up to five)
- Imaging ordered (up to two)
- Referrals and hospital admissions (up to two).

### Statistical Analysis

The confidence interval (CI) is calculated as the rate estimate  $\pm$  (1.96 x standard error). The CI is interpreted as “we are 95% confident that the true population value lies between the lower and upper value”. Please note that in some cases, if there were less than three observations (n) in the row, no 95% CIs are provided as data were insufficient to calculate a meaningful estimate. The analysis used procedures in SAS v9.3 that calculate standard errors which adjust for the cluster survey design<sup>1</sup>. Keep in mind when reading the report, where BEACH data are reported in a standard set of categories (e.g. types of Medicare claimable encounters), a missing category means there were no occurrences of the event (e.g. home visits missing indicates no home visits were done for this condition/group of conditions). Also, where the most common 30 or 60 cases are listed (e.g. most frequent patient reasons for encounter, table 3.4), only the 30 with the highest frequency of occurrence have been printed. While there may have been other cases with a lower frequency of occurrence, the list has been cut off at 30.

### TABLE A: Summary of all medications – Allopurinol – Apr05-Mar06

This table provides the overall rated prescription/ GP supply of allopurinol. It includes a count of the total number of prescriptions for allopurinol during the time period, the prescription/supply rate for each generic within this group of drugs, and a breakdown of the rate at which the participating GPs recorded the script as a generic name and the relative rate of prescription of each of the product names for this generic. The prescribing rates are presented in terms of the rate per 100 BEACH encounters, the rate per 100 problems managed and the percentage of all medications that is accounted for by this medication. If the selected medication is a class of drugs then the percent of this class that is accounted for by each generic or specific product is listed in the column titled “% of allopurinol”. The “% generic” column shows the percentage of a generic accounted for by each specific product.

The “national annual estimated meds” gives the estimated number of GP contacts where the specified medication was prescribed/supplied/advised in the selected year across Australia. It is calculated as [*the number of specified medications prescribed/supplied/advised (n) / the total number of recorded encounters within the specified study period*] X *the number of general practice consultations claimed from Medicare in the specified year*. If you have requested

---

<sup>1</sup> SAS Institute. SAS/STAT® User's guide, Version 9.3. Cary, NC: SAS Institute Inc, 2012.

encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

The table below lists the number of non-specialist GP Medicare services for each specified BEACH year (April-March). If your report is based on multiple BEACH years (e.g. 2003–04 to 2005–06) the rate has been extrapolated to the average annual GP consultations over the multiple years, e.g.  $(96,300,000 + 98,200,000 + 101,100,000) / 3$ .

	<b>BEACH year</b>	<b>Annual GP consultations<sup>^</sup></b>
1	1998–99	102,600,000
2	1999–00	101,500,000
3	2000–01	100,600,000
4	2001–02	99,900,000
5	2002–03	96,900,000
6	2003–04	96,300,000
7	2004–05	98,200,000
8	2005–06	101,100,000
9	2006–07	103,400,000
10	2007–08	109,500,000
11	2008–09	113,000,000
12	2009–10	116,600,000
13	2010–11	119,200,000
14	2011-12	123,900,000
15	2012-13	

<sup>^</sup>Annual GP consultations are rounded to the nearest 100,000.

Available online at : <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-jun12-contents>

Then select Group BA Tables - Selected Aggregates by Broad Type of Service and by Financial Year followed by Group B1A Tables – Number of Services

## **TABLE B: Summary of 'new' medications – Allopurinol – Apr05-Mar06**

The above analysis is repeated for the allopurinol which are classified as 'new'. A *new medication* is one that is being prescribed/supplied/advised for the management of this problem in this patient for the first time.

## **TABLE C: Summary of 'continued' medications – Allopurinol – Apr05-Mar06**

The above analysis is repeated for the allopurinol which are classified as 'continued'. A *continued medication* is one that is being prescribed/supplied/advised as a continuation or a repeat of a previous therapy for this problem.

### **SECTION 1: SUMMARY OF ENCOUNTERS**

#### **TABLE 1a: Type of encounter – Allopurinol – Apr05-Mar06**

Definitions of the categories are as follows:

**Encounter (enc):** Any professional interchange between a patient and a GP.

**Direct encounters:** Encounters where there is a face-to-face meeting of the patient and the GP.

**No charge:** Encounters where no fee (Medicare bulk billing or other) is received for the service provided.

**MBS items by GPs:** Encounters claimable through the MBS. The following groups are claimable through the relevant MBS item numbers.

**Short surgery consults:** (Level A) A short encounter which requires limited examination and management.

**Standard surgery consults:** (Level B) An encounter of less than 20 minutes duration, which requires an examination of the patient and an implementation of a management plan in relation to at least one of the problems.

**Long surgery consults:** (Level C) An encounter with duration between 20 and 40 minutes, which involves taking a detailed history and implementing a management plan for at least one of the problems.

**Prolonged surgery consults:** (Level D) An encounter with a duration of more than 40 minutes, which involves taking an exhaustive history, a comprehensive examination, the arrangement of necessary investigations and implementing a management plan for at least one of the problems.

**Home visits:** Encounters that take place in the patient's home and a MBS home visit item number(s) are recorded.

**Hospital:** Encounters that take place with a patient in a hospital setting, and a MBS hospital item number(s) are recorded.

**Residential aged care facility:** Encounters that take place in a residential aged care facility (RACF) and an MBS RACF item number is recorded.

**Case conferences:** Encounters that are covered by a MBS item number for a case conference.

**Chronic disease management:** Encounters that are covered by a MBS chronic disease management item number(s).

**GP mental health care:** Encounters that are covered by a MBS GP mental health care plan item number(s).

**Health assessments:** Encounters that are covered by a MBS item number for a health assessment.

**Incentive payments:** Encounters where MBS incentive payment items are recorded.

**Other items:** Medicare item numbers that do not identify the place of encounter and are not covered by any of the above item numbers.

**Worker's compensation:** Encounters claimable through Worker's Compensation.

**Other paid (hospital, state etc):** All other direct services covered by other funding services e.g. insurance, employer, state health dept, hospitals, etc.

**Direct encounters with practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded though the patient was said to have been seen by the GP.

**Indirect encounters:** Encounters where there is no face-to-face meeting between the patient and the GP but a service is provided (e.g. prescription, referral).

**Indirect encounters with practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded, and the patient was said *not* to have been seen by the GP.

**Unspecified practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded, and it is unknown whether the patient was/wasn't seen by the GP.

#### **TABLE 1a 2: Summary of data base: services – Allopurinol – Apr05-Mar06**

This table will only be valid if **all** of your data are from the period April 2005 onwards. If your data are based on years that cross April 2005, this table is not valid. This is because, prior to April 2005 only one item number could be recorded. From April 2005 onwards, up to three Medicare item numbers could be recorded on an encounter form. The denominator for the column titled "per 100 encs" is all encounters (from table 1a). This table is useful when allocating direct costs against management of a selected problem.

#### **TABLE 1b: Summary of database: morbidity and management – Allopurinol – Apr05-Mar06**

This table describes the characteristics of the problems and medications that are included in this report. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

**General practitioners** is the number of GPs who recorded encounters that are included in this report (i.e. those who prescribed/supplied/advised allopurinol within the specified data period).

**Problem managed:** A formal statement of the providers' understanding of a health problem presented by the patient, family or community. It can be described in terms of a disease, symptom/complaint, social problem or ill-defined condition managed at the encounter (up to four per encounter).

**New problems:** The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem but excluding the presentation of a problem first assessed by another provider.

**Old problems:** A previously assessed problem that requires ongoing care; includes follow-up for a problem or an initial presentation of a problem previously assessed by another provider.

**Chronic problem:** A medical condition characterised by a combination of the following characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of recurrence or deterioration, a poor prognosis, and consequences that impact on an individual's quality of life.

**Chronic problem:** A medical condition not characterised by those characteristics listed above.

**Work related:** A problem that is viewed as having resulted or been significantly exacerbated from a work-related activity or workplace exposures.

**NB:** The numbers of 'new problems' and of 'old problems' add to equal the total number of problems. 'Chronic problems' and 'work-related problems' are two additional independent methods of classifying the types of problems at encounters. Individual problems within these two categories will have already been counted either as 'new' or as 'old' problems.

**Medications:** The total number of the selected medication/s that are prescribed, advised for over-the-counter (OTC) purchase or provided from the GP's own supplies (GP supplied). Up to four medications can be recorded for each problem.

**Prescribed:** The total number of the selected medication/s that were prescribed by the GP.

**GP supplied:** The total number of the selected medication/s that were provided from the practice supplies e.g. sample or vaccine.

**Advised OTC:** The total number of the selected medication/s that were advised to be purchased over-the-counter i.e. an S2 or S3 product.

**New:** A medication that is prescribed/supplied/advised is being used for the management of the problem for the first time.

**Continued:** A medication that is prescribed/supplied/advised as a continuation or a repeat of previous therapy for the problem.

## SECTION 2: GENERAL PRACTITIONERS

Tables 2.1 and 2.2 display the characteristics of the GPs who prescribed/supplied/advised allopurinol at least once.

### TABLE 2.1: General practitioners: age by sex – Allopurinol – Apr05-Mar06

This table displays the age-sex distribution of the GPs who were included in this analysis. These data were collected from the GP Characteristics Questionnaire which is completed by all GPs participating in the BEACH project (see Appendix 2 in BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/4/9781743320198\\_ONLINE.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/4/9781743320198_ONLINE.pdf) >).



## TABLE 2.2: GP characteristics – Allopurinol – Apr05-Mar06

This table displays the characteristics of the GPs, collected from the GP Characteristics Questionnaire. Definitions of the categories are as follows:

**Years in general practice:** The number of years the GP has been in general practice.

**Sessions:** The number of sessions worked per week.

**Practice size-Number of GPs at practice:** The number of GPs in the participating GPs main practice (including the participating GP).

**Practice size-FTE GPs at practice:** The number of full time equivalent GPs in the participating GPs main practice (including the participating GP).

**Practice state:** The state which the GPs main practice is in.

**RRMA of main practice** (Rural, Remote & Metropolitan Area Classification) classifies the location of the practice to one of 7 categories

<<http://www.ruraldoc.com.au>>.

**ASGC of main practice** (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories

<<http://www.abs.gov.au>>.

**Country of Graduation:** The GPs reported country of graduation.

**>50% consults NESB:** (non-English speaking background) the GPs assessment of the proportion of their consultations conducted in a language other than English.

**Hold FRACGP** is whether the participating GP is a Fellow of the Royal Australian College of General Practitioners.

**Practice accredited** is whether the practice is accredited.

## SECTION 3: PATIENT CHARACTERISTICS

### TABLE 3.1: Summary of database: patients – Allopurinol – Apr05-Mar06

This table describes the characteristics of the patients who received the selected medication at their encounter. Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

**Sex and age** distributions are provided. The age groupings correspond with significant trends in GP service use.

**HCC card:** Encounters with patients who hold an Australian Government health care card (HCC).

**VA card:** Encounters with Veteran's Affairs card holders (not necessarily charged through VA).

**NESB:** Encounters with patients whose primary language spoken at home is not English (non-English speaking background).

**Aboriginal only:** Patients who identify themselves as being Aboriginal and not Torres Strait Islander.

**Torres Strait Islander only:** Patients who identify themselves as being Torres Strait Islander and not Aboriginal.

**Aboriginal & Torres Strait Islander:** Patients who identify themselves as being both an Aboriginal and a Torres Strait Islander.

**Aboriginal and/or TSI:** Patients who are Aboriginal or Torres Strait Islanders, or both.

**New to practice:** Patients who had not been seen previously in this practice.

**Seen previously:** Patients who had been seen previously in this practice.

**State/territory:** The patients' state/territory is provided, based on the postcode reported by the patient.

**RRMA of main practice** (Rural, Remote & Metropolitan Area Classification) classifies the location of the practice to one of 7 categories

<<http://www.ruraldoc.com.au>>.

**ASGC of main practice** (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories

<<http://www.abs.gov.au>>.

#### **TABLE 3.2.1: Age by sex of patient at encounter – Allopurinol – Apr05-Mar06**

This table displays the distribution of male and female patients that have been included in this analysis, by their age group.

#### **TABLE 3.2.2: Age/sex specific rates of Allopurinol – Apr05-Mar06**

This table displays the management rate of the specified medication(s) by each age–sex category. The denominator for the age sex– specific rate is the total number of encounters with patients (or specified type of patients) in each age–sex category.

#### **TABLE 3.3: Reasons for encounters (RFEs) – ICPC chapter – Allopurinol – Apr05-Mar06**

**Reasons for encounter** (RFE) reflect the patients' expressed demand for care as perceived and recorded by the GP. Up to three RFEs can be recorded at each encounter. A RFE is not directly linked to a problem managed. This table gives the number of RFEs recorded for encounters where the selected medication was prescribed/supplied/advised. RFEs have been grouped using ICPC-2 PLUS chapter headings which correspond approximately to the main body systems with additional chapters for social and psychological problems. Problems which cross multiple body systems are grouped together as "General & unspecified".

Each RFE is coded using ICPC-2 PLUS and classified to ICPC-2. There are seventeen chapters in ICPC-2 which are mainly based on body systems. Details on these chapters can be found at <[www.fmrc.org.au/icpc2/tech.htm](http://www.fmrc.org.au/icpc2/tech.htm)>.

This table shows the distribution of RFEs by ICPC-2 chapter at the encounters where allopurinol was prescribed/supplied/advised.

**TABLE 3.4: Most frequent patient reasons for encounter (RFEs) – Allopurinol – Apr05-Mar06**

This table shows the 30 most common RFEs recorded at the encounters where allopurinol was prescribed/supplied/advised. The RFE label is the individual ICPC rubric label unless denoted by \*, which indicates a grouping of multiple ICPC rubrics under the same RFE (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>). Number of observations (n), % of total RFEs, rate per 100 encounters and 95% CIs are provided for each data point.

**SECTION 4: ALL MEDICATIONS****TABLE 4.1: Medication source – Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase. Refer to notes on Table 1b for definitions of prescribed/supplied/advised medications). Medication source is of greatest interest where the selected medication can be either prescribed or advised (e.g. paracetamol). The data are presented in three levels –

*Total prescribed/supplied/advised allopurinol*

*Generic allopurinol*

*Individual product recorded by the GP*

At each level, the medication is expressed as the number of observations (n), as a percentage of the total allopurinol that were prescribed/supplied/advised, and upper and lower CIs. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each medication.

**TABLE 4.2: Medication status – Allopurinol – Apr05-Mar06**

This table displays the status of each medication as being either new or continued (refer to notes on Table 1b for definitions of new and continued), and these figures are expressed as a percentage of the total allopurinol. The first three columns also appear in Table A and notes for these are provided in the explanatory notes for Table A. The right section of the table shows the number that was new/continued, and the percentage of each medication.

**TABLE 4.3.1: Prescribed regimen – Allopurinol (generic level) – Apr05-Mar06**

The prescribed regimen of the selected medication is presented in this table at generic level. “Prescribed regimen” includes prescribed, supplied and advised medications. The prescribed dose, units, quantity and frequency (quantity + frequency usually = number of times per day) are provided for each medication. The column labelled “% of generic group” represents the percentage of a generic accounted for by the medication with a particular regimen. It is calculated as *[the number of each generic with an exact regimen / the total number of a specific generic] X 100*.

**TABLE 4.3.2: Prescribed regimen – Allopurinol (product level) – Apr05-Mar06**

The prescribed regimen of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.3.2.

**TABLE 4.4.1: Prescribed daily dose – Allopurinol (generic level) – Apr05-Mar06**

Medications that are prescribed/supplied/advised by the GP, for which complete regimen and dosage (in micrograms, milligrams or grams) information are recorded, are included in the calculation of the prescribed daily dose (PDD). The number of medications (n) and the prescribed daily doses for each generic medication are shown. Complete dosage and regimen information are required for calculation of PDD. The column labelled “% of generic group” is calculated as: *[the number of each generic with this PDD/the total number of each generic with a valid PDD] X 100*.

**TABLE 4.4.2: Prescribed daily dose – Allopurinol (product level) – Apr05-Mar06**

The prescribed daily dose of the selected medication is presented in this table at product level. Explanations for the columns parallel those in Table 4.4.1.

**TABLE 4.5: Average prescribed daily dose – Allopurinol – Apr05-Mar06**

This table provides the mean PDD, median PDD, minimum and maximum PDD for the selected medication, at generic and product level. “Average prescribed daily dose” includes prescribed, supplied and advised medications. Note that the median is often a more reliable measure of central tendency than the mean, which is influenced by outliers.

**TABLE 4.6: Average number of repeats – Allopurinol – Apr05-Mar06**

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats, at generic and product level. Again note that the median is often a more reliable measure of central tendency than the average which is influenced by outliers.

**SECTION 5: NEW MEDICATIONS****TABLE 5.1: Medication source – ‘new’ Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.2: Medication status – ‘new’ Allopurinol – Apr05-Mar06**

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.3.1: Prescribed regimen – ‘new’ Allopurinol (generic level) – Apr05-Mar06**

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.3.2: Prescribed regimen – ‘new’ Allopurinol (product level) – Apr05-Mar06**

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.4.1: Prescribed daily dose – ‘new’ Allopurinol (generic level) – Apr05-Mar06**

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.4.2: Prescribed daily dose – ‘new’ Allopurinol (product level) – Apr05-Mar06**

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.5: Average prescribed daily dose – ‘new’ Allopurinol – Apr05-Mar06**

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

**TABLE 5.6: Average number of repeats – ‘new’ Allopurinol – Apr05-Mar06**

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘new’ (see definition Table 1b).

## **SECTION 6: CONTINUED MEDICATIONS**

### **TABLE 6.1: Medication source – ‘continued’ Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (i.e. prescribed by the GP, supplied by the GP, or advised for OTC purchase (similar to Table 4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

### **TABLE 6.2: Medication status – ‘continued’ Allopurinol – Apr05-Mar06**

This table displays the status of each medication as being either new or continued (similar to Table 4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

### **TABLE 6.3.1: Prescribed regimen – ‘continued’ Allopurinol (generic level) – Apr05-Mar06**

This table displays the prescribed regimen of the selected medication at generic level (similar to Table 4.3.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

### **TABLE 6.3.2: Prescribed regimen – ‘continued’ Allopurinol (product level) – Apr05-Mar06**

This table displays the prescribed regimen of the selected medication at product level (similar to Table 4.3.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

### **TABLE 6.4.1: Prescribed daily dose – ‘continued’ Allopurinol (generic level) – Apr05-Mar06**

This table displays the prescribed daily dose of the selected medication at generic level (similar to Table 4.4.1) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

### **TABLE 6.4.2: Prescribed daily dose – ‘continued’ Allopurinol (product level) – Apr05-Mar06**

This table displays the prescribed daily dose of the selected medication at product level (similar to Table 4.4.2) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

**TABLE 6.5: Average prescribed daily dose – ‘continued’ Allopurinol – Apr05-Mar06**

This table displays the average prescribed daily dose of the selected medication, at generic and product level (similar to Table 4.5) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

**TABLE 6.6: Average number of repeats – ‘continued’ Allopurinol – Apr05-Mar06**

This table displays the average number of repeats of the selected medication, at generic and product level (similar to Table 4.6) for encounters where the medication was classified as ‘continued’ (see definition Table 1b).

**SECTION 7: PROBLEMS MANAGED****TABLE 7.1.1: Problems managed – ICPC chapter – Allopurinol – Apr05-Mar06**

This table described the distribution, by ICPC chapter, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The column labelled “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

**TABLE 7.1.2: Problems managed – Allopurinol – Apr05-Mar06**

This table described the distribution, by the individual ICPC rubric label, of all problems (includes all diagnoses, diseases, ill-defined conditions and complaints) for which the GP prescribed/supplied/advised the selected medication at the encounter. The asterisk (\*) indicates a grouping of multiple ICPC rubrics under the same problem (concept) label, e.g. “Hypertension\*” groups the ICPC rubrics of Hypertension Uncomplicated (K86) and Hypertension Complicated (K87). (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

The column “% of GPs” includes the proportion of all GPs within the data period who prescribed/supplied/advised at least one of the selected medications to manage the specific problem. “% of specific problem” includes the proportion of the specific problem managed with at least one of the selected medications at the encounter. Number of problems (n), % of allopurinol problems, and 95% confidence interval (CI) are also provided for each data point.

**TABLE 7.2: Medication source by individual problem managed – Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed. The right section of the table shows the number that was prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.2.1: Medication source by individual problem managed – ‘New’ Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed, for encounters where the medication was classified as ‘new’ (see definition Table 1b). The right section of the table shows the number of ‘new’ medications that were prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.2.2: Medication source by individual problem managed – ‘Continued’ Allopurinol – Apr05-Mar06**

This table displays the method by which the medication was provided (similar to Table 4.1) by the problem managed, for encounters where the medication was classified as ‘continued’ (see definition Table 1b). The right section of the table shows the number of ‘continued’ medications that were prescribed/supplied/advised, and the percentage of each problem (refer to notes on Table 1b for definitions of prescribed/supplied/advised medications).

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.3: Medication status by individual problem managed – Allopurinol – Apr05-Mar06**

This table displays the status of the selected medication (similar to Table 4.2) by the problem managed. The right section of the table shows the number that was new/continued, and the percentage of each problem (refer to notes on Table 1b for definitions).

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).



**TABLE 7.4: Prescribed regimen by individual problem managed for each generic – Allopurinol – Apr05-Mar06**

The prescribed regimen of the selected medication is presented for each of the problems for which the selected medication was prescribed/supplied/advised (similar to Table 4.3.1).

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.5: Prescribed daily dose by individual problem managed for each generic – Allopurinol – Apr05-Mar06**

For each problem managed with the selected medication, this table provides the prescribed daily dose recorded by the GPs. For further notes refer to Table 4.4.1.

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.6: Average prescribed daily dose by individual problem managed for each generic – Allopurinol – Apr05-Mar06**

For each problem managed with the selected medication, this table provides the mean, median, minimum and maximum PDD recorded by the GPs. For further notes refer to Table 4.5.

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

**TABLE 7.7: Average number of repeats by individual problem managed – Allopurinol – Apr05-Mar06**

For each problem managed with the selected medication this table provides the mean, median, minimum and maximum number of repeats recorded by the GPs. For further notes refer to Table 4.6.

The \* indicates a grouping of multiple ICPC problem rubrics under the same problem (concept) label. (See Appendix 4 of the BEACH annual report, General practice activity in Australia 2011–12, <[http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix\\_4\\_YEAR\\_14.pdf](http://ses.library.usyd.edu.au/bitstream/2123/8675/5/Appendix_4_YEAR_14.pdf)>).

BEACH Survey Report - Analysis date: 03SEP13

Table A: Summary of all medications  
- Allopurinol Apr05-Mar06 wgted

Generic	Product	n	Rate per 100 all encs		Rate per 100 probs		% of all meds	% of Allopurinol	% of generic	National annual	Lower 95% CI	Upper 95% CI
			Lower 95% CI	Upper 95% CI	estimated meds							
Total Allopurinol		302	0.30	0.26	0.34	0.20	0.28	.	.	298900	258400	339300
Allopurinol		302	0.30	0.26	0.34	0.20	0.28	100.00	.	298900	258400	339300
	Zyloprim tablets 300 mg	118	0.12	0.09	0.14	0.08	0.11	39.09	39.09	116800	90900	142700
	Progout tablets 300 mg	65	0.06	0.05	0.08	0.04	0.06	21.67	21.67	64800	48000	81500
	Allopurinol NOS	44	0.04	0.03	0.06	0.03	0.04	14.63	14.63	43700	29100	58400
	Zyloprim tablets 100 mg	34	0.03	0.02	0.05	0.02	0.03	11.24	11.24	33600	21100	46100
	Progout tablets 100 mg	23	0.02	0.01	0.03	0.02	0.02	7.70	7.70	23000	10700	35300
	Zyloprim NOS	6	0.01	0.00	0.01	0.00	0.01	1.97	1.97	5900	0	13700
	Allopurinol tablets 100 mg	6	0.01	0.00	0.01	0.00	0.01	1.91	1.91	5700	600	10800
	Allopurinol tablets 300 mg	2	0.00	.	.	0.00	0.00	0.73	0.73	2200	.	.
	Allopurinol capsules 300 mg	1	0.00	.	.	0.00	0.00	0.35	0.35	1100	.	.
	Progout NOS	1	0.00	.	.	0.00	0.00	0.29	0.29	900	.	.
	Allohexal tablets 100 mg	1	0.00	.	.	0.00	0.00	0.24	0.24	700	.	.
	Capurate capsules 300 mg	1	0.00	.	.	0.00	0.00	0.18	0.18	600	.	.

Refer to explanatory notes for the base used in calculation of national annual estimated medications, and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 101993 and 149088 respectively.

BEACH Survey Report - Analysis date: 03SEP13

Table B: Summary of 'new' medications  
 - Allopurinol Apr05-Mar06 wgted

Generic	Product	Rate per		Rate per		% of all meds	% of Allopurinol	% of generic	National annual estimated meds	Lower 95% CI	Upper 95% CI
		n	encs	Lower 95% CI	Upper 95% CI						
Total Allopurinol		29	0.03	0.02	0.04	0.02	0.03	.	29000	17700	40300
Allopurinol		29	0.03	0.02	0.04	0.02	0.03	100.00	29000	17700	40300
	Zyloprim tablets 300 mg	10	0.01	0.00	0.02	0.01	0.01	33.28	9600	2900	16400
	Zyloprim tablets 100 mg	8	0.01	0.00	0.01	0.01	0.01	27.70	8000	1900	14200
	Allopurinol NOS	7	0.01	0.00	0.01	0.00	0.01	22.56	6500	2300	10800
	Progout tablets 300 mg	2	0.00	.	.	0.00	0.00	7.22	2100	.	.
	Allopurinol tablets 300 mg	1	0.00	.	.	0.00	0.00	4.94	1400	.	.
	Progout tablets 100 mg	1	0.00	.	.	0.00	0.00	3.31	1000	.	.
	Allopurinol tablets 100 mg	0	0.00	.	.	0.00	0.00	1.00	300	.	.

Refer to explanatory notes for the base used in calculation of national annual estimated medications,  
 and the number of estimated medications is rounded to the nearest 100.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 101993 and 149088 respectively.

Table C: Summary 'continued' medications  
 - Allopurinol Apr05-Mar06 wgted

Generic	Product	Rate per		Rate per		% of all meds	% of Allopurinol	% of generic	National annual estimated		Lower 95% CI	Upper 95% CI
		n	all encs	Lower 95% CI	Upper 95% CI				100 probs	meds		
Total Allopurinol		272	0.27	0.23	0.31	0.18	0.26	.	.	269900	231100	308700
Allopurinol		272	0.27	0.23	0.31	0.18	0.26	100.00	.	269900	231100	308700
	Zyloprim tablets 300 mg	108	0.11	0.08	0.13	0.07	0.10	39.72	39.72	107200	82200	132200
	Progout tablets 300 mg	63	0.06	0.05	0.08	0.04	0.06	23.22	23.22	62700	46300	79000
	Allopurinol NOS	38	0.04	0.02	0.05	0.03	0.04	13.78	13.78	37200	23100	51200
	Zyloprim tablets 100 mg	26	0.03	0.01	0.04	0.02	0.02	9.47	9.47	25600	14900	36200
	Progout tablets 100 mg	22	0.02	0.01	0.03	0.01	0.02	8.17	8.17	22100	9900	34300
	Zyloprim NOS	6	0.01	0.00	0.01	0.00	0.01	2.18	2.18	5900	0	13700
	Allopurinol tablets 100 mg	5	0.01	0.00	0.01	0.00	0.01	2.01	2.01	5400	400	10400
	Allopurinol capsules 300 mg	1	0.00	.	.	0.00	0.00	0.39	0.39	1100	.	.
	Progout NOS	1	0.00	.	.	0.00	0.00	0.32	0.32	900	.	.
	Allopurinol tablets 300 mg	1	0.00	.	.	0.00	0.00	0.27	0.27	700	.	.
	Allohexal tablets 100 mg	1	0.00	.	.	0.00	0.00	0.27	0.27	700	.	.
	Capurate capsules 300 mg	1	0.00	.	.	0.00	0.00	0.20	0.20	600	.	.

Refer to explanatory notes for the base used in calculation of national annual estimated medications,  
 and the number of estimated medications is rounded to the nearest 100.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status,  
 assumed to be 'continued'.

The denominators used to calculate column labelled 'Rate per 100 all encs' and 'Rate per 100 probs' are 101993 and 149088 respectively.

Table 1a: Type of encounter  
 - Allopurinol Apr05-Mar06 wgted

Data	n	%	Lower 95% CI	Upper 95% CI
General practitioners	240	.	.	.
Encounters	301	.	.	.
Direct encounters	277	96.8	94.8	98.8
No charge	2	0.9	0.0	2.1
MBS items by GPs	274	95.9	93.6	98.3
- Short surgery consultations	4	1.3	0.0	2.8
- Standard surgery consultations	241	84.3	80.1	88.5
- Long surgery consultations	21	7.3	4.5	10.1
- Home visits	5	1.7	0.2	3.1
- Residential aged care facility	1	0.5	0.0	1.2
- Health assessments	0	0.1	0.0	0.3
- Incentive payments	2	0.8	0.0	1.8
Indirect encounters	9	3.2	1.2	5.2
Missing	15	.	.	.

The indirect encounters with item numbers (eg: chronic disease management item or case conference item) are counted under both medicare paid items and indirect encounters. Therefore, the number of no charge, medicare paid, worker's compensation and other paid do not always add up to the number of direct encounters.

During the BEACH study period April 1998 to March 2005, GPs were instructed to record the lowest Medicare item number (e.g.: an A1 item number) if multiple item numbers applied.

From April 2005 onwards, multiple Medicare item numbers (up to 3) could be recorded on an encounter form. The lowest item in the encounter was selected and analysed in this table.

This provides comparable results to those reported before April 2005.

Table 1a 2: Distribution of grouped Medicare service item numbers - Allopurinol Apr05-Mar06 wgt'd

From April 2005 onwards, Multiple Medicare service item numbers (up to 3) could be recorded for each encounter

Service Item Group	N (recorded items)	Percent	Per 100 encs	Lower 95% CI	Upper 95% CI
Surgery consultations	265	94.6	88.2	84.3	92.1
Hospital residential aged care and home visits	6	2.2	2.1	0.6	3.6
Health assessments	0	0.1	0.1	.	.
Practice incentive payments	2	0.8	0.7	.	.
Practice nurse/aboriginal health worker/allied health services	3	1.1	1.0	0.0	2.3
Therapeutic procedures	1	0.4	0.4	.	.
Pathology services	2	0.8	0.7	.	.
	.	.	.	.	.
Total Medicare service items recorded	281	100.0	93.2	89.0	97.3

The denominator for the column titled 'Per 100 encs' is all encounters (from Table 1a)

BEACH Survey Report - Analysis date: 03SEP13

Table 1b: Summary of database: morbidity and management  
 - Allopurinol Apr05-Mar06 wgted

Data	n	Per 100 probs	Lower 95% CI	Upper 95% CI
General practitioners	240	.	.	.
Encounters	301	.	.	.
Reasons for encounter	574	.	.	.
Problems managed	301	.	.	.
- New problems	20	6.6	3.7	9.4
- Old problems	281	93.4	90.6	96.3
- Chronic problem	237	78.6	73.0	84.1
- Non-chronic problem	64	21.4	15.9	27.0
Medications	302	100.1	99.9	100.4
- Prescribed	300	99.7	99.2	100.2
- GP supplied	1	0.4	.	.
- Advised OTC	0	0.0	.	.
- New	29	9.7	6.0	13.4
- Continued	272	90.4	86.8	94.1

Table 2.1: General practitioners: age by sex  
 - Allopurinol Apr05-Mar06 wgted

The FREQ Procedure

Table of gpage by gpsex

gpage(GP age)      gpsex(GP sex)

Frequency Row Pct Col Pct	Male	Female	Total
< 35 years	0 0.00 0.00	5.67494 100.00 9.64	5.67494
35-44 years	27.0114 61.03 15.93	17.2449 38.97 29.29	44.2563
45-54 years	60.2982 77.22 35.57	17.7858 22.78 30.20	78.0839
55+ years	82.2067 81.89 48.49	18.1807 18.11 30.87	100.387
Total	169.516	58.8863	228.403

Frequency Missing = 4.1531238715



Table 2.2: GP characteristics - Allopurinol Apr05-Mar06 wgted

Data	n	%
Years in general practice	.	.
< 2 years	3	1.2
2-5 years	8	3.5
6-10 years	25	10.7
11-19 years	47	20.3
20+ years	148	64.4
Missing	3	.
Sessions	.	.
<5 per week	21	9.2
6-10 per week	182	78.2
11+ per week	29	12.6
Size of practice	.	.
Solo GP	36	15.5
2-4 GPs	97	42.0
5+ GPs	98	42.6
Missing	2	.
Practice state	.	.
ACT	6	2.4
NSW	101	43.4
VIC	37	15.9
QLD	42	18.3
SA	16	6.7
WA	23	9.9
TAS	5	2.3
NT	3	1.1
RRMA of main practic	.	.
Capital	151	64.9
Oth Met	16	7.0
Lge Rur	9	4.0
Sm Rur	19	8.1
Oth Rur	32	13.6

^ Number of sessions worked per week not collected after Mar09

\* Practice size-Num GPs at practice not collected between Apr07-Mar09

\*\* Practice size-FTE GPs at practice not collected prior to Apr07

Table 2.2: GP characteristics - Allopurinol Apr05-Mar06 wgted

Data	n	%
Rem Cen	2	0.8
Oth Rem, Offsh	4	1.6
ASGC of main practic	.	.
Major Cities	162	69.9
Inner Regional	44	18.7
Outer Regional	21	8.9
Remote	5	2.1
Very Remote	1	0.4
Country of graduatio	.	.
Australia	166	71.4
New Zealand	4	1.8
Asia	25	10.9
UK/Ireland	18	7.9
Europe	6	2.7
Africa	12	5.0
Pacific	1	0.4
> 50% consults NESB	.	.
Yes	10	4.4
No	221	95.6
Missing	1	.
Hold FRACGP	.	.
Yes	82	35.4
No	149	64.6
Missing	2	.
Practice Accredited	.	.
Yes	188	81.2
No	44	18.8
Missing	1	.

^ Number of sessions worked per week not collected after Mar09

\* Practice size-Num GPs at practice not collected between Apr07-Mar09

\*\* Practice size-FTE GPs at practice not collected prior to Apr07

BEACH Survey Report - Analysis date: 03SEP13

Table 3.1: Summary of database: patients - Allopurinol Apr05-Mar06 wgted

Data	n	%	Lower 95% CI	Upper 95% CI
Patients	301	.	.	.
- Males	238	79.3	74.3	84.3
- Females	62	20.7	15.7	25.7
- Missing sex	1	.	.	.
.	.	.	.	.
- 5-14 years	2	0.6	0.0	1.9
- 25-44 years	21	7.0	3.8	10.1
- 45-64 years	123	41.2	35.0	47.3
- 65-74 years	81	27.1	21.7	32.4
- 75+ years	72	24.2	19.0	29.4
- Missing age	2	.	.	.
.	.	.	.	.
- HCC card	161	57.1	50.2	64.1
- No HCC card	121	42.9	35.9	49.8
- Missing HCC	19	.	.	.
.	.	.	.	.
- VA card	16	5.7	2.9	8.5
- No VA card	263	94.3	91.5	97.1
- Missing VA	22	.	.	.
.	.	.	.	.
- NESB	37	13.3	7.9	18.8
- English speaking background	242	86.7	81.2	92.1
- Missing NESB status	22	.	.	.
.	.	.	.	.
- Aboriginal and/or TSI	1	0.5	0.0	1.1
- Non-indigenous	278	99.5	98.9	100.0
- Missing ATSI status	22	.	.	.
.	.	.	.	.
- New to practice	5	1.6	0.3	3.0
- Seen previously	293	98.4	97.0	99.7
- Missing status	3	.	.	.

Table 3.2.1: Age by sex of patient at encounter  
 - Allopurinol Apr05-Mar06 wgted

The FREQ Procedure

Table of sex by agegp

sex(Sex of patient) agegp(Patient Age-group)

Frequency Row Pct Col Pct	5-14	25-44	45-64	65-74	75+	Total
Male	1.91529 0.81 100.00	17.6052 7.47 84.64	104.066 44.13 84.56	63.3217 26.85 79.42	48.8899 20.73 67.67	235.798
Female	0 0.00 0.00	3.19423 5.15 15.36	19.0014 30.66 15.44	16.4118 26.48 20.58	23.3597 37.70 32.33	61.9671
Total	1.91529	20.7994	123.067	79.7334	72.2496	297.765

Frequency Missing = 3.3036529403

Table 3.2.2 Age/sex specific rates of Allopurinol Apr05-Mar06 wgt'd

Patient characteristics	Number of encounters with at least one Allopurinol	Number of specific encounters	Per 100 specific encounters	Lower 95% CI	Upper 95% CI
Total	301	101993	0.30	0.26	0.34
<1 year	0	2098	0.00	.	.
1-4 years	0	4301	0.00	.	.
5-14 years	2	6100	0.03	0.00	0.09
15-24 years	0	9486	0.00	.	.
25-44 years	21	24226	0.09	0.05	0.13
45-64 years	123	27980	0.44	0.35	0.53
65-74 years	81	12302	0.66	0.51	0.81
75+ years	72	14731	0.49	0.37	0.61
Missing age	2	769	0.28	0.00	0.59
Males	238	44486	0.53	0.45	0.62
Females	62	56719	0.11	0.08	0.14
Missing sex	1	788	0.15	0.00	0.36

Table 3.3: Reasons for encounters (RFEs)- ICPC chapter  
 - Allopurinol Apr05-Mar06 wgt

RFE chapter	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
General & unspecified	193	33.6	63.9	54.8	73.1
Endocrine & metabolic	118	20.7	39.3	32.3	46.3
Circulatory	77	13.4	25.5	20.2	30.9
Musculoskeletal	59	10.3	19.7	13.2	26.2
Respiratory	37	6.5	12.4	7.5	17.4
Skin	31	5.3	10.2	6.3	14.1
Urology	12	2.1	4.0	1.2	6.8
Psychological	9	1.5	2.9	0.8	4.9
Blood	8	1.4	2.6	0.6	4.7
Eye	7	1.2	2.4	0.4	4.4
Neurological	7	1.2	2.2	0.6	3.9
Ear	6	1.0	2.0	0.1	3.9
Male genital system	6	1.0	1.9	0.2	3.5
Social	2	0.4	0.8	.	.
Digestive	2	0.3	0.5	.	.
Female genital system	0	0.1	0.1	.	.
.	.	.	.	.	.
Subtotal	574	100.0	.	.	.
.	.	.	.	.	.
Total RFEs	574	100.0	190.5	179.9	201.1

Table 3.4: Most frequent patient reasons for encounters (RFEs)  
- Allopurinol Apr05-Mar06 wgted

RFE label	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
Prescription all*	183	31.8	60.7	51.5	69.8
Gout	56	9.7	18.5	13.2	23.8
Test results*	27	4.6	8.8	4.8	12.9
Cardiac check-up*	24	4.2	7.9	4.8	11.1
Hypertension*	21	3.7	7.1	3.9	10.4
General check-up*	20	3.5	6.6	3.2	10.0
Foot/toe symptom/complaint	18	3.1	5.9	1.2	10.6
Preventive immun/vacc/meds-all*	14	2.5	4.7	1.9	7.5
Cough	7	1.2	2.4	0.6	4.1
Diabetes*	6	1.0	1.8	0.3	3.4
Blood test blood/lymph	6	1.0	1.8	0.0	3.7
Arthritis (excl. OA and rheumatoid)*	5	0.9	1.7	0.0	4.4
Back complaint*	5	0.9	1.7	0.0	3.7
Sleep disturbance	5	0.8	1.6	0.0	3.3
Swelling*	5	0.8	1.5	0.0	3.3
Swollen ankles/oedema	5	0.8	1.5	0.0	3.3
Joint symptom/complaint NOS	4	0.7	1.4	0.1	2.7
Lipid disorders*	4	0.7	1.4	0.0	2.9
Knee symptom/complaint	4	0.7	1.4	0.1	2.8
Follow-up encounter unspecified endocrine/metabolic	4	0.7	1.4	0.0	2.7
Vertigo/dizziness	4	0.7	1.3	0.1	2.6
Rash*	4	0.7	1.3	0.0	2.8
Upper respiratory infection, acute	4	0.7	1.2	0.0	2.6
Blood test NOS	4	0.6	1.2	0.0	2.4
Follow-up encounter unspecified urinary	3	0.6	1.2	0.0	2.6
Shortness of breath/dyspnoea	3	0.6	1.1	0.0	2.8
Clarify/discuss patient RFE/demand NOS	3	0.6	1.1	0.0	2.5
Urinary calculus	3	0.6	1.1	0.0	2.4
Follow-up encounter unspecified NOS	3	0.5	1.0	0.0	2.2
Skin symptom/complaint, other	3	0.5	1.0	.	.
Subtotal	457	79.6	.	.	.
	.	.	.	.	.

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

Table 3.4: Most frequent patient reasons for encounters (RFEs)  
 - Allopurinol Apr05-Mar06 wgted

RFE label	n	% of total RFEs	Per 100 Allopurinol encs	Lower 95% CI	Upper 95% CI
Other RFEs	117	20.4	.	.	.
Total RFEs	574	100.0	190.5	179.9	201.1

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes  
 See explanatory notes (Section 3) for URL where groupings are described



BEACH Survey Report - Analysis date: 03SEP13

Table 4.1: Medication source  
- Allopurinol Apr05-Mar06 wgttd

Generic	Product	n	% of Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP n	% of specific meds
Total Allopurinol		302	100.0	.	.	300	99.6	.	.	1	0.4
Allopurinol		302	100.0	100.0	100.0	300	99.6	.	.	1	0.4
	Allopurinol NOS	44	14.6	10.0	19.3	44	99.2	.	.	0	0.8
	Allopurinol capsules 300 mg	1	0.4	.	.	1	100.0	.	.	.	.
	Allopurinol tablets 100 mg	6	1.9	0.2	3.6	6	100.0	.	.	.	.
	Allopurinol tablets 300 mg	2	0.7	.	.	2	89.1	.	.	0	10.9
	Progout NOS	1	0.3	.	.	1	100.0	.	.	.	.
	Progout tablets 100 mg	23	7.7	3.7	11.7	23	100.0	.	.	.	.
	Progout tablets 300 mg	65	21.7	16.6	26.7	65	99.3	.	.	0	0.7
	Capurate capsules 300 mg	1	0.2	.	.	1	100.0	.	.	.	.
	Zyloprim NOS	6	2.0	0.0	4.6	6	100.0	.	.	.	.
	Zyloprim tablets 100 mg	34	11.2	7.3	15.2	34	100.0	.	.	.	.
	Zyloprim tablets 300 mg	118	39.1	32.6	45.6	118	99.8	.	.	0	0.2
	Allohexal tablets 100 mg	1	0.2	.	.	1	100.0	.	.	.	.

Table 4.2: Medication status  
 - Allopurinol Apr05-Mar06 wgted

Generic	Product	n	% of Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		302	100.0	.	29	9.7	272	90.3
Allopurinol		302	100.0	.	29	9.7	272	90.3
	Allopurinol NOS	44	14.6	14.6	7	15.0	38	85.0
	Allopurinol capsules 300 mg	1	0.4	0.4	.	.	1	100.0
	Allopurinol tablets 100 mg	6	1.9	1.9	0	5.1	5	94.9
	Allopurinol tablets 300 mg	2	0.7	0.7	1	66.0	1	34.0
	Progout NOS	1	0.3	0.3	.	.	1	100.0
	Progout tablets 100 mg	23	7.7	7.7	1	4.2	22	95.8
	Progout tablets 300 mg	65	21.7	21.7	2	3.2	63	96.8
	Capurate capsules 300 mg	1	0.2	0.2	.	.	1	100.0
	Zyloprim NOS	6	2.0	2.0	.	.	6	100.0
	Zyloprim tablets 100 mg	34	11.2	11.2	8	23.9	26	76.1
	Zyloprim tablets 300 mg	118	39.1	39.1	10	8.3	108	91.7
	Allohexal tablets 100 mg	1	0.2	0.2	.	.	1	100.0

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

Table 4.3.1 : Prescribed regimen\*  
 - Allopurinol (generic level) Apr05-Mar06 wgted

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	7	.		.		2.4
Allopurinol	4	.		1	daily	1.2
Allopurinol	1	10	mg	3	daily	0.4
Allopurinol	1	50	mg	.		0.3
Allopurinol	1	50	mg	1	daily	0.3
Allopurinol	50	100	mg	1	daily	16.7
Allopurinol	3	100	mg	2	daily	1.0
Allopurinol	7	150	mg	1	daily	2.3
Allopurinol	18	200	mg	1	daily	6.0
Allopurinol	2	200	mg	2	daily	0.5
Allopurinol	0	300	mg	.		0.1
Allopurinol	203	300	mg	1	daily	67.2
Allopurinol	4	300	mg	2	daily	1.3
Allopurinol	1	600	mg	1	daily	0.5

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 4.3.2 : Prescribed regimen\*  
 - Allopurinol (product level) Apr05-Mar06 wgted

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.	.	.		0.5
Allopurinol NOS	2	.	.	1	daily	0.6
Allopurinol NOS	1	10	mg	3	daily	0.4
Allopurinol NOS	10	100	mg	1	daily	3.4
Allopurinol NOS	1	100	mg	2	daily	0.2
Allopurinol NOS	1	150	mg	1	daily	0.2
Allopurinol NOS	4	200	mg	1	daily	1.3
Allopurinol NOS	24	300	mg	1	daily	8.0
Allopurinol capsules 300 mg	1	300	mg	1	daily	0.4
Allopurinol tablets 100 mg	0	50	mg	1	daily	0.2
Allopurinol tablets 100 mg	3	100	mg	1	daily	0.9
Allopurinol tablets 100 mg	0	100	mg	2	daily	0.1
Allopurinol tablets 100 mg	2	200	mg	1	daily	0.7
Allopurinol tablets 300 mg	2	300	mg	1	daily	0.7
Progout NOS	1	.	.	.		0.3
Progout tablets 100 mg	16	100	mg	1	daily	5.3
Progout tablets 100 mg	1	150	mg	1	daily	0.4
Progout tablets 100 mg	4	200	mg	1	daily	1.5
Progout tablets 100 mg	2	200	mg	2	daily	0.5
Progout tablets 300 mg	2	.	.	1	daily	0.6
Progout tablets 300 mg	1	150	mg	1	daily	0.2
Progout tablets 300 mg	61	300	mg	1	daily	20.1
Progout tablets 300 mg	1	300	mg	2	daily	0.3
Progout tablets 300 mg	1	600	mg	1	daily	0.4
Capurate capsules 300 mg	1	300	mg	1	daily	0.2
Zyloprim NOS	2	.	.	.		0.6
Zyloprim NOS	0	100	mg	1	daily	0.1
Zyloprim NOS	4	300	mg	1	daily	1.3
Zyloprim tablets 100 mg	2	.	.	.		0.6
Zyloprim tablets 100 mg	1	50	mg	.		0.3
Zyloprim tablets 100 mg	0	50	mg	1	daily	0.1
Zyloprim tablets 100 mg	20	100	mg	1	daily	6.7
Zyloprim tablets 100 mg	2	100	mg	2	daily	0.6
Zyloprim tablets 100 mg	8	200	mg	1	daily	2.5

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 4.3.2 : Prescribed regimen\*  
 - Allopurinol (product level) Apr05-Mar06 wgted

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 100 mg	1	300	mg	1	daily	0.4
Zyloprim tablets 300 mg	1	.		.		0.5
Zyloprim tablets 300 mg	4	150	mg	1	daily	1.4
Zyloprim tablets 300 mg	0	300	mg	.		0.1
Zyloprim tablets 300 mg	109	300	mg	1	daily	36.1
Zyloprim tablets 300 mg	3	300	mg	2	daily	1.0
Zyloprim tablets 300 mg	0	600	mg	1	daily	0.1
Allohexal tablets 100 mg	1	100	mg	1	daily	0.2

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 4.4.1 : Prescribed daily dose\*  
 - Allopurinol (generic level) Apr05-Mar06 wgtd

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	30	mg	0.4
Allopurinol	1	50	mg	0.3
Allopurinol	50	100	mg	17.4
Allopurinol	7	150	mg	2.4
Allopurinol	21	200	mg	7.2
Allopurinol	203	300	mg	70.0
Allopurinol	2	400	mg	0.5
Allopurinol	5	600	mg	1.8

\*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.

Table 4.4.2 : Prescribed daily dose\*  
 - Allopurinol (product level) Apr05-Mar06 wgted

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	1	30	mg	0.4
Allopurinol NOS	10	100	mg	3.5
Allopurinol NOS	1	150	mg	0.2
Allopurinol NOS	5	200	mg	1.6
Allopurinol NOS	24	300	mg	8.3
Allopurinol capsules 300 mg	1	300	mg	0.4
Allopurinol tablets 100 mg	0	50	mg	0.2
Allopurinol tablets 100 mg	3	100	mg	0.9
Allopurinol tablets 100 mg	3	200	mg	0.9
Allopurinol tablets 300 mg	2	300	mg	0.8
Progout tablets 100 mg	16	100	mg	5.5
Progout tablets 100 mg	1	150	mg	0.5
Progout tablets 100 mg	4	200	mg	1.5
Progout tablets 100 mg	2	400	mg	0.5
Progout tablets 300 mg	1	150	mg	0.3
Progout tablets 300 mg	61	300	mg	21.0
Progout tablets 300 mg	2	600	mg	0.8
Capurate capsules 300 mg	1	300	mg	0.2
Zyloprim NOS	0	100	mg	0.1
Zyloprim NOS	4	300	mg	1.3
Zyloprim tablets 100 mg	0	50	mg	0.1
Zyloprim tablets 100 mg	20	100	mg	7.0
Zyloprim tablets 100 mg	9	200	mg	3.2
Zyloprim tablets 100 mg	1	300	mg	0.4
Zyloprim tablets 300 mg	4	150	mg	1.4
Zyloprim tablets 300 mg	109	300	mg	37.6
Zyloprim tablets 300 mg	3	600	mg	1.1
Allohexal tablets 100 mg	1	100	mg	0.3

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 4.5: Average prescribed daily dose\*  
 - Allopurinol Apr05-Mar06 wgted

Generic	Product	n	Mean PDD	Measure	Median		Minimum	Measure	Maximum	Measure
					PDD	Measure				
Allopurinol		290	258.7	mg	300	mg	30	mg	600	mg
	Allopurinol NOS	41	228.4	mg	300	mg	30	mg	300	mg
	Allopurinol capsules 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Allopurinol tablets 100 mg	6	139.7	mg	100	mg	50	mg	200	mg
	Allopurinol tablets 300 mg	2	300.0	mg	300	mg	300	mg	300	mg
	Progout tablets 100 mg	23	142.4	mg	100	mg	100	mg	400	mg
	Progout tablets 300 mg	64	308.7	mg	300	mg	150	mg	600	mg
	Capurate capsules 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim NOS	4	280.9	mg	300	mg	100	mg	300	mg
	Zyloprim tablets 100 mg	31	136.9	mg	100	mg	50	mg	300	mg
	Zyloprim tablets 300 mg	116	302.7	mg	300	mg	150	mg	600	mg
	Allohexal tablets 100 mg	1	100.0	mg	100	mg	100	mg	100	mg

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.



Table 4.6: Average number of repeats  
 - Allopurinol Apr05-Mar06 wgted

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		248	2.0	2	0	5
	Allopurinol NOS	31	1.8	2	0	5
	Allopurinol capsules 300 mg	1	2.0	2	2	2
	Allopurinol tablets 100 mg	6	2.2	2	0	5
	Allopurinol tablets 300 mg	2	2.0	2	2	2
	Progout tablets 100 mg	20	1.5	2	0	5
	Progout tablets 300 mg	56	2.0	2	0	5
	Zyloprim NOS	1	2.0	2	2	2
	Zyloprim tablets 100 mg	27	1.5	1	0	5
	Zyloprim tablets 300 mg	102	2.1	2	0	5
	Allohexal tablets 100 mg	1	2.0	2	2	2

BEACH Survey Report - Analysis date: 03SEP13

Table 5.1: Medication source  
 - 'new' Allopurinol Apr05-Mar06 wgted

Generic	Product	n	% of 'new' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		29.2410	100.000	.	.	28.8936	98.812	.	.	0.34744	1.18820
Allopurinol		29.2410	100.000	100.000	100.000	28.8936	98.812	.	.	0.34744	1.18820
	Allopurinol NOS	6.5967	22.560	8.271	36.849	6.2493	94.733	.	.	0.34744	5.26686
	Allopurinol tablets 100 mg	0.2920	0.999	.	.	0.2920	100.000	.	.	.	.
	Allopurinol tablets 300 mg	1.4431	4.935	.	.	1.4431	100.000	.	.	.	.
	Progout tablets 100 mg	0.9673	3.308	.	.	0.9673	100.000	.	.	.	.
	Progout tablets 300 mg	2.1100	7.216	.	.	2.1100	100.000	.	.	.	.
	Zyloprim tablets 100 mg	8.1010	27.704	8.826	46.582	8.1010	100.000	.	.	.	.
	Zyloprim tablets 300 mg	9.7307	33.278	13.389	53.166	9.7307	100.000	.	.	.	.

Table 5.2: Medication status  
 - 'new' Allopurinol Apr05-Mar06 wgted

Generic	Product	n	% of 'new' Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		29.2410	100.000	.	29.2410	100	.	.
Allopurinol		29.2410	100.000	.	29.2410	100	.	.
	Allopurinol NOS	6.5967	22.560	22.5599	6.5967	100	.	.
	Allopurinol tablets 100 mg	0.2920	0.999	0.9985	0.2920	100	.	.
	Allopurinol tablets 300 mg	1.4431	4.935	4.9353	1.4431	100	.	.
	Progout tablets 100 mg	0.9673	3.308	3.3082	0.9673	100	.	.
	Progout tablets 300 mg	2.1100	7.216	7.2160	2.1100	100	.	.
	Zyloprim tablets 100 mg	8.1010	27.704	27.7043	8.1010	100	.	.
	Zyloprim tablets 300 mg	9.7307	33.278	33.2777	9.7307	100	.	.

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

Table 5.3.1 : Prescribed regimen (All medications)\*  
 - 'new' Allopurinol (generic level) Apr05-Mar06 wgted

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	0.8206	.		1	daily	2.8
Allopurinol	1.0040	50	mg	.		3.4
Allopurinol	0.3376	50	mg	1	daily	1.2
Allopurinol	7.4001	100	mg	1	daily	25.3
Allopurinol	2.0448	200	mg	1	daily	7.0
Allopurinol	17.6340	300	mg	1	daily	60.3

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03SEP13

Table 5.3.2 : 'Prescribed' regimen (All medications)\*  
 - 'new' Allopurinol (product level) Apr05-Mar06 wgted

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	0.82058	.		1	daily	2.8
Allopurinol NOS	2.56859	100	mg	1	daily	8.8
Allopurinol NOS	3.20757	300	mg	1	daily	11.0
Allopurinol tablets 100 mg	0.29198	100	mg	1	daily	1.0
Allopurinol tablets 300 mg	1.44313	300	mg	1	daily	4.9
Progout tablets 100 mg	0.96735	100	mg	1	daily	3.3
Progout tablets 300 mg	2.11004	300	mg	1	daily	7.2
Zyloprim tablets 100 mg	1.00402	50	mg	.		3.4
Zyloprim tablets 100 mg	0.33757	50	mg	1	daily	1.2
Zyloprim tablets 100 mg	3.57214	100	mg	1	daily	12.2
Zyloprim tablets 100 mg	2.04477	200	mg	1	daily	7.0
Zyloprim tablets 100 mg	1.14250	300	mg	1	daily	3.9
Zyloprim tablets 300 mg	9.73074	300	mg	1	daily	33.3

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03SEP13

Table 5.4.1 : 'Prescribed' daily dose (All medications)\*  
 - 'new' Allopurinol (generic level) Apr05-Mar06 wgttd

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	0	50	mg	1.2
Allopurinol	7	100	mg	27.0
Allopurinol	2	200	mg	7.5
Allopurinol	18	300	mg	64.3

\*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.

BEACH Survey Report - Analysis date: 03SEP13

Table 5.4.2 : 'Prescribed' daily dose (All medications)\*  
 - 'new' Allopurinol (product level) Apr05-Mar06 wgted

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	3	100	mg	9.4
Allopurinol NOS	3	300	mg	11.7
Allopurinol tablets 100 mg	0	100	mg	1.1
Allopurinol tablets 300 mg	1	300	mg	5.3
Progout tablets 100 mg	1	100	mg	3.5
Progout tablets 300 mg	2	300	mg	7.7
Zyloprim tablets 100 mg	0	50	mg	1.2
Zyloprim tablets 100 mg	4	100	mg	13.0
Zyloprim tablets 100 mg	2	200	mg	7.5
Zyloprim tablets 100 mg	1	300	mg	4.2
Zyloprim tablets 300 mg	10	300	mg	35.5

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.

Table 5.5: Average 'prescribed' daily dose (All medications)\*  
 - 'new' Allopurinol Apr05-Mar06 wgted

Generic	Product	n	Mean PDD	Measure	Median		Minimum	Measure	Maximum	Measure
					PDD	Measure				
Allopurinol		27	235.5	mg	300	mg	50	mg	300	mg
	Allopurinol NOS	6	211.1	mg	300	mg	100	mg	300	mg
	Allopurinol tablets 100 mg	0	100.0	mg	100	mg	100	mg	100	mg
	Allopurinol tablets 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Progout tablets 100 mg	1	100.0	mg	100	mg	100	mg	100	mg
	Progout tablets 300 mg	2	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim tablets 100 mg	7	158.6	mg	100	mg	50	mg	300	mg
	Zyloprim tablets 300 mg	10	300.0	mg	300	mg	300	mg	300	mg

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.



Table 5.6: Average number of repeats  
 - 'new' Allopurinol Apr05-Mar06 wgted

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		26.14	1.65562	2	0	5
	Allopurinol NOS	6.16	1.35620	2	0	2
	Allopurinol tablets 100 mg	0.29	5.00000	5	5	5
	Allopurinol tablets 300 mg	1.44	2.00000	2	2	2
	Progout tablets 100 mg	0.97	0.00000	0	0	0
	Progout tablets 300 mg	2.11	1.22370	1	1	2
	Zyloprim tablets 100 mg	6.68	1.36513	1	0	2
	Zyloprim tablets 300 mg	8.49	2.22388	2	0	5

BEACH Survey Report - Analysis date: 03SEP13

Table 6.1: Medication source  
 - 'continued' Allopurinol Apr05-Mar06 wgtD

Generic	Product	n	% of 'continued' Allopurinol	Lower 95% CI	Upper 95% CI	Prescribed n	% of specific meds	Advised n	% of specific meds	GP supplied n	% of specific meds
Total Allopurinol		272	100.0	.	.	271	99.7	.	.	1	0.3
Allopurinol		272	100.0	100.0	100.0	271	99.7	.	.	1	0.3
	Allopurinol NOS	38	13.8	8.9	18.7	38	100.0	.	.	.	.
	Allopurinol capsules 300 mg	1	0.4	.	.	1	100.0	.	.	.	.
	Allopurinol tablets 100 mg	5	2.0	0.1	3.9	5	100.0	.	.	.	.
	Allopurinol tablets 300 mg	1	0.3	.	.	1	68.0	.	.	0	32.0
	Progout NOS	1	0.3	.	.	1	100.0	.	.	.	.
	Progout tablets 100 mg	22	8.2	3.8	12.5	22	100.0	.	.	.	.
	Progout tablets 300 mg	63	23.2	17.8	28.7	63	99.3	.	.	0	0.7
	Capurate capsules 300 mg	1	0.2	.	.	1	100.0	.	.	.	.
	Zyloprim NOS	6	2.2	0.0	5.1	6	100.0	.	.	.	.
	Zyloprim tablets 100 mg	26	9.5	5.6	13.3	26	100.0	.	.	.	.
	Zyloprim tablets 300 mg	108	39.7	32.8	46.6	108	99.8	.	.	0	0.2
	Allohexal tablets 100 mg	1	0.3	.	.	1	100.0	.	.	.	.

Table 6.2: Medication status  
 - 'continued' Allopurinol Apr05-Mar06 wgtD

Generic	Product	n	% of 'continued' Allopurinol	% of generic	New n	% of specific meds	Continued n	% of specific meds
Total Allopurinol		272	100.0	.	.	.	272	100.0
Allopurinol		272	100.0	.	.	.	272	100.0
	Allopurinol NOS	38	13.8	13.8	.	.	38	100.0
	Allopurinol capsules 300 mg	1	0.4	0.4	.	.	1	100.0
	Allopurinol tablets 100 mg	5	2.0	2.0	.	.	5	100.0
	Allopurinol tablets 300 mg	1	0.3	0.3	.	.	1	100.0
	Progout NOS	1	0.3	0.3	.	.	1	100.0
	Progout tablets 100 mg	22	8.2	8.2	.	.	22	100.0
	Progout tablets 300 mg	63	23.2	23.2	.	.	63	100.0
	Capurate capsules 300 mg	1	0.2	0.2	.	.	1	100.0
	Zyloprim NOS	6	2.2	2.2	.	.	6	100.0
	Zyloprim tablets 100 mg	26	9.5	9.5	.	.	26	100.0
	Zyloprim tablets 300 mg	108	39.7	39.7	.	.	108	100.0
	Allohexal tablets 100 mg	1	0.3	0.3	.	.	1	100.0

Note: The 'continued' medications include medications specified as 'continued' and medications with missing status, assumed to be 'continued'.

Table 6.3.1 : 'Prescribed' regimen (All medications)\*  
 - 'continued' Allopurinol (generic level) Apr05-Mar06 wgtd

Generic	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	7	.		.		2.6
Allopurinol	3	.		1	daily	1.0
Allopurinol	1	10	mg	3	daily	0.4
Allopurinol	0	50	mg	1	daily	0.2
Allopurinol	43	100	mg	1	daily	15.7
Allopurinol	3	100	mg	2	daily	1.1
Allopurinol	7	150	mg	1	daily	2.5
Allopurinol	16	200	mg	1	daily	5.8
Allopurinol	2	200	mg	2	daily	0.6
Allopurinol	0	300	mg	.		0.1
Allopurinol	185	300	mg	1	daily	67.9
Allopurinol	4	300	mg	2	daily	1.4
Allopurinol	1	600	mg	1	daily	0.5

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03SEP13

Table 6.3.2 : 'Prescribed' regimen (All medications)\*  
 - 'continued' Allopurinol (product level) Apr05-Mar06 wgtd

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol NOS	1	.	.	.		0.5
Allopurinol NOS	1	.	.	1	daily	0.4
Allopurinol NOS	1	10	mg	3	daily	0.4
Allopurinol NOS	8	100	mg	1	daily	2.8
Allopurinol NOS	1	100	mg	2	daily	0.3
Allopurinol NOS	1	150	mg	1	daily	0.3
Allopurinol NOS	4	200	mg	1	daily	1.4
Allopurinol NOS	21	300	mg	1	daily	7.7
Allopurinol capsules 300 mg	1	300	mg	1	daily	0.4
Allopurinol tablets 100 mg	0	50	mg	1	daily	0.2
Allopurinol tablets 100 mg	2	100	mg	1	daily	0.9
Allopurinol tablets 100 mg	0	100	mg	2	daily	0.2
Allopurinol tablets 100 mg	2	200	mg	1	daily	0.8
Allopurinol tablets 300 mg	1	300	mg	1	daily	0.3
Progout NOS	1	.	.	.		0.3
Progout tablets 100 mg	15	100	mg	1	daily	5.5
Progout tablets 100 mg	1	150	mg	1	daily	0.5
Progout tablets 100 mg	4	200	mg	1	daily	1.6
Progout tablets 100 mg	2	200	mg	2	daily	0.6
Progout tablets 300 mg	2	.	.	1	daily	0.6
Progout tablets 300 mg	1	150	mg	1	daily	0.3
Progout tablets 300 mg	59	300	mg	1	daily	21.5
Progout tablets 300 mg	1	300	mg	2	daily	0.4
Progout tablets 300 mg	1	600	mg	1	daily	0.4
Capurate capsules 300 mg	1	300	mg	1	daily	0.2
Zyloprim NOS	2	.	.	.		0.6
Zyloprim NOS	0	100	mg	1	daily	0.1
Zyloprim NOS	4	300	mg	1	daily	1.4
Zyloprim tablets 100 mg	2	.	.	.		0.6
Zyloprim tablets 100 mg	17	100	mg	1	daily	6.2
Zyloprim tablets 100 mg	2	100	mg	2	daily	0.7
Zyloprim tablets 100 mg	6	200	mg	1	daily	2.0
Zyloprim tablets 300 mg	1	.	.	.		0.5
Zyloprim tablets 300 mg	4	150	mg	1	daily	1.5

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03SEP13

Table 6.3.2 : 'Prescribed' regimen (All medications)\*  
 - 'continued' Allopurinol (product level) Apr05-Mar06 wgttd

Product	n	Dose	Units	Quantity	Frequency	% of generic group
Zyloprim tablets 300 mg	0	300	mg	.		0.1
Zyloprim tablets 300 mg	99	300	mg	1	daily	36.4
Zyloprim tablets 300 mg	3	300	mg	2	daily	1.1
Zyloprim tablets 300 mg	0	600	mg	1	daily	0.1
Allohexal tablets 100 mg	1	100	mg	1	daily	0.3

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

BEACH Survey Report - Analysis date: 03SEP13

Table 6.4.1 : 'Prescribed' daily dose (All medications)\*  
 - 'continued' Allopurinol (generic level) Apr05-Mar06 wgt

Generic	n	Prescribed daily dose	Units	% of generic group
Allopurinol	1	30	mg	0.5
Allopurinol	0	50	mg	0.2
Allopurinol	43	100	mg	16.3
Allopurinol	7	150	mg	2.6
Allopurinol	19	200	mg	7.2
Allopurinol	185	300	mg	70.6
Allopurinol	2	400	mg	0.6
Allopurinol	5	600	mg	2.0

\*This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.

BEACH Survey Report - Analysis date: 03SEP13

Table 6.4.2 : 'Prescribed' daily dose (All medications)\*  
 - 'continued' Allopurinol (product level) Apr05-Mar06 wgtd

Product	n	Prescribed daily dose	Units	% of generic group
Allopurinol NOS	1	30	mg	0.5
Allopurinol NOS	8	100	mg	2.9
Allopurinol NOS	1	150	mg	0.3
Allopurinol NOS	5	200	mg	1.7
Allopurinol NOS	21	300	mg	8.0
Allopurinol capsules 300 mg	1	300	mg	0.4
Allopurinol tablets 100 mg	0	50	mg	0.2
Allopurinol tablets 100 mg	2	100	mg	0.9
Allopurinol tablets 100 mg	3	200	mg	1.0
Allopurinol tablets 300 mg	1	300	mg	0.3
Progout tablets 100 mg	15	100	mg	5.7
Progout tablets 100 mg	1	150	mg	0.5
Progout tablets 100 mg	4	200	mg	1.7
Progout tablets 100 mg	2	400	mg	0.6
Progout tablets 300 mg	1	150	mg	0.3
Progout tablets 300 mg	59	300	mg	22.3
Progout tablets 300 mg	2	600	mg	0.8
Capurate capsules 300 mg	1	300	mg	0.2
Zyloprim NOS	0	100	mg	0.2
Zyloprim NOS	4	300	mg	1.5
Zyloprim tablets 100 mg	17	100	mg	6.4
Zyloprim tablets 100 mg	7	200	mg	2.8
Zyloprim tablets 300 mg	4	150	mg	1.6
Zyloprim tablets 300 mg	99	300	mg	37.9
Zyloprim tablets 300 mg	3	600	mg	1.2
Allohexal tablets 100 mg	1	100	mg	0.3

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.



Table 6.5: Average 'prescribed' daily dose (All medications)\*  
 - 'continued' Allopurinol Apr05-Mar06 wgtD

Generic	Product	n	Mean PDD	Measure	Median		Minimum	Measure	Maximum	Measure
					PDD	Measure				
Allopurinol		262	261.2	mg	300	mg	30	mg	600	mg
	Allopurinol NOS	35	231.3	mg	300	mg	30	mg	300	mg
	Allopurinol capsules 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Allopurinol tablets 100 mg	5	141.8	mg	100	mg	50	mg	200	mg
	Allopurinol tablets 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Progout tablets 100 mg	22	144.3	mg	100	mg	100	mg	400	mg
	Progout tablets 300 mg	62	309.0	mg	300	mg	150	mg	600	mg
	Capurate capsules 300 mg	1	300.0	mg	300	mg	300	mg	300	mg
	Zyloprim NOS	4	280.9	mg	300	mg	100	mg	300	mg
	Zyloprim tablets 100 mg	24	130.5	mg	100	mg	100	mg	200	mg
	Zyloprim tablets 300 mg	106	303.0	mg	300	mg	150	mg	600	mg
	Allohexal tablets 100 mg	1	100.0	mg	100	mg	100	mg	100	mg

\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen  
 and dosage information were recorded.

BEACH Survey Report - Analysis date: 03SEP13

Table 6.6: Average number of repeats  
 - 'continued' Allopurinol Apr05-Mar06 wgt

Generic	Product	n	Mean repeats	Median repeats	Minimum	Maximum
Allopurinol		221	2.0	2	0	5
	Allopurinol NOS	25	1.9	2	0	5
	Allopurinol capsules 300 mg	1	2.0	2	2	2
	Allopurinol tablets 100 mg	5	2.0	2	0	5
	Allopurinol tablets 300 mg	1	2.0	2	2	2
	Progout tablets 100 mg	19	1.6	2	0	5
	Progout tablets 300 mg	54	2.0	2	0	5
	Zyloprim NOS	1	2.0	2	2	2
	Zyloprim tablets 100 mg	20	1.6	1	0	5
	Zyloprim tablets 300 mg	94	2.1	2	0	5
	Allohexal tablets 100 mg	1	2.0	2	2	2

BEACH Survey Report - Analysis date: 03SEP13

Table 7.1.1: Problems managed- ICPC chapter  
- Allopurinol Apr05-Mar06 wgted

Problem label	n probs	% of GPs*	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem**
Endocrine & metabolic	241	20.1	80.0	74.4	85.6	2.0
General & unspecified	35	2.9	11.7	7.1	16.2	0.2
Circulatory	11	1.0	3.5	0.9	6.1	0.1
Urology	7	0.8	2.2	0.5	3.9	0.2
Musculoskeletal	6	0.8	1.9	0.5	3.4	0.0
Male genital system	2	0.2	0.5	.	.	0.1
Blood	0	0.1	0.1	.	.	0.0
.	.	.	.	.	.	.
Total problems	301	.	100.0	.	.	.

\* The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.

\*\* Proportion of specific problem managed with at least one selected medication at the encounter.

Table 7.1.2: Problems managed  
- Allopurinol Apr05-Mar06 wgttd

Problem label	n probs	% of GPs**	% of Allopurinol problems	Lower 95% CI	Upper 95% CI	% of specific problem***
Gout	218	18.6	72.6	66.4	78.7	37.6
Prescription all*	33	2.8	10.9	6.4	15.3	1.6
Endocrine/metabolic/nutritional disease, other	19	1.6	6.2	2.8	9.6	3.6
Hypertension*	8	0.7	2.8	0.3	5.3	0.1
Urinary calculus	4	0.4	1.3	0.0	2.6	3.2
Arthritis (excl. OA and rheumatoid)*	3	0.5	1.2	0.0	2.3	0.6
Preventive immun/vacc/meds-all*	3	0.2	1.1	0.0	2.8	0.1
Diabetes*	2	0.2	0.7	.	.	0.1
Limited function/disability urinary	1	0.1	0.4	.	.	4.4
Limited function/disability NOS	1	0.1	0.4	.	.	1.4
Lipid disorders*	1	0.1	0.4	.	.	0.0
Rheumatic fever/heart disease	1	0.1	0.3	.	.	14.6
Heart failure	1	0.1	0.3	.	.	0.1
Prostatitis/seminal vesiculitis	1	0.1	0.3	.	.	2.0
Genital disease, other (male) (incl breast)	1	0.1	0.3	.	.	1.2
Urinary disease, other	1	0.1	0.2	.	.	0.8
Chronic kidney disease*	1	0.1	0.2	.	.	0.3
Joint symptom/complaint NOS	1	0.1	0.2	.	.	0.2
Benign/uncertain neoplasm blood/lymph	0	0.1	0.1	.	.	1.8
Limited function/disability cardiovascular	0	0.1	0.1	.	.	4.5
Haematuria	0	0.1	0.1	.	.	0.2
.	.	.	.	.	.	.
Total problems	301	.	100.0	.	.	.

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* The Proportion of all GPs within the data period prescribed, advised or supplied at least one selected medication to manage the specific problem.

\*\*\* Poportion of specific problem managed with at least one selected medication at the encounter.

Table 7.2: Medication source by individual problem managed  
 - Allopurinol Apr05-Mar06 wgted

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	219	72.6	218	99.4	.	.	1	0.6
Prescription all*	33	10.8	33	100.0	.	.	.	.
Endocrine/metabolic/nutritional disease, other	19	6.2	19	100.0	.	.	.	.
Hypertension*	8	2.8	8	100.0	.	.	.	.
Urinary calculus	4	1.3	4	100.0	.	.	.	.
Arthritis (excl. OA and rheumatoid)*	3	1.2	3	100.0	.	.	.	.
Preventive immun/vacc/meds-all*	3	1.1	3	100.0	.	.	.	.
Diabetes*	2	0.7	2	100.0	.	.	.	.
Limited function/disability urinary	1	0.4	1	100.0	.	.	.	.
Limited function/disability NOS	1	0.4	1	100.0	.	.	.	.
Lipid disorders*	1	0.4	1	100.0	.	.	.	.
Rheumatic fever/heart disease	1	0.3	1	100.0	.	.	.	.
Heart failure	1	0.3	1	100.0	.	.	.	.
Prostatitis/seminal vesiculitis	1	0.3	1	100.0	.	.	.	.
Genital disease, other (male) (incl breast)	1	0.3	1	100.0	.	.	.	.
Urinary disease, other	1	0.2	1	100.0	.	.	.	.
Chronic kidney disease*	1	0.2	1	100.0	.	.	.	.
Joint symptom/complaint NOS	1	0.2	1	100.0	.	.	.	.
Benign/uncertain neoplasm blood/lymph	0	0.1	0	100.0	.	.	.	.
Limited function/disability cardiovascular	0	0.1	0	100.0	.	.	.	.
Haematuria	0	0.1	0	100.0	.	.	.	.
	=====		=====		=====		=====	
	302		300		0		1	

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.2.1: Medication source by individual problem managed - 'New'  
 - Allopurinol Apr05-Mar06 wgted

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	23	78.3	23	98.5	.	.	0	1.5
Prescription all*	2	6.5	2	100.0	.	.	.	.
Endocrine/metabolic/nutritional disease, other	2	5.9	2	100.0	.	.	.	.
Prostatitis/seminal vesiculitis	1	2.8	1	100.0	.	.	.	.
Genital disease, other (male) (incl breast)	1	2.7	1	100.0	.	.	.	.
Joint symptom/complaint NOS	1	2.1	1	100.0	.	.	.	.
Arthritis (excl. OA and rheumatoid)*	0	1.6	0	100.0	.	.	.	.
	=====		=====		=====		=====	
	29		29		0		0	

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* The number of selected medications prescribed, advised over the counter, or supplied by GPs  
 for the specific problem.

Table 7.2.2: Medication source by individual problem managed - 'Continued'  
 - Allopurinol Apr05-Mar06 wgted

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	Prescribed n	% of meds for specific prob	Advised n	% of meds for specific prob	GP supplied n	% of meds for specific prob
Gout	196	72.0	195	99.5	.	.	1	0.5
Prescription all*	31	11.3	31	100.0	.	.	.	.
Endocrine/metabolic/nutritional disease, other	17	6.2	17	100.0	.	.	.	.
Hypertension*	8	3.1	8	100.0	.	.	.	.
Urinary calculus	4	1.4	4	100.0	.	.	.	.
Preventive immun/vacc/meds-all*	3	1.3	3	100.0	.	.	.	.
Arthritis (excl. OA and rheumatoid)*	3	1.1	3	100.0	.	.	.	.
Diabetes*	2	0.8	2	100.0	.	.	.	.
Limited function/disability urinary	1	0.4	1	100.0	.	.	.	.
Limited function/disability NOS	1	0.4	1	100.0	.	.	.	.
Lipid disorders*	1	0.4	1	100.0	.	.	.	.
Rheumatic fever/heart disease	1	0.4	1	100.0	.	.	.	.
Heart failure	1	0.3	1	100.0	.	.	.	.
Urinary disease, other	1	0.3	1	100.0	.	.	.	.
Chronic kidney disease*	1	0.2	1	100.0	.	.	.	.
Benign/uncertain neoplasm blood/lymph	0	0.2	0	100.0	.	.	.	.
Limited function/disability cardiovascular	0	0.1	0	100.0	.	.	.	.
Haematuria	0	0.1	0	100.0	.	.	.	.
	=====		=====		=====		=====	
	272		271		0		1	

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.

Table 7.3: Medication status by individual problem managed  
 - Allopurinol Apr05-Mar06 wgted

Problem - ICPC 2 Rubric	n meds**	% of Allopurinol	New n	% of meds for specific prob	Continued n	% of meds for specific prob
Gout	219	72.6	23	10.5	196	89.5
Prescription all*	33	10.8	2	5.8	31	94.2
Endocrine/metabolic/nutritional disease, other	19	6.2	2	9.2	17	90.8
Hypertension*	8	2.8	.	.	8	100.0
Urinary calculus	4	1.3	.	.	4	100.0
Arthritis (excl. OA and rheumatoid)*	3	1.2	0	13.8	3	86.2
Preventive immun/vacc/meds-all*	3	1.1	.	.	3	100.0
Diabetes*	2	0.7	.	.	2	100.0
Limited function/disability urinary	1	0.4	.	.	1	100.0
Limited function/disability NOS	1	0.4	.	.	1	100.0
Lipid disorders*	1	0.4	.	.	1	100.0
Rheumatic fever/heart disease	1	0.3	.	.	1	100.0
Heart failure	1	0.3	.	.	1	100.0
Prostatitis/seminal vesiculitis	1	0.3	1	100.0	.	.
Genital disease, other (male) (incl breast)	1	0.3	1	100.0	.	.
Urinary disease, other	1	0.2	.	.	1	100.0
Chronic kidney disease*	1	0.2	.	.	1	100.0
Joint symptom/complaint NOS	1	0.2	1	100.0	.	.
Benign/uncertain neoplasm blood/lymph	0	0.1	.	.	0	100.0
Limited function/disability cardiovascular	0	0.1	.	.	0	100.0
Haematuria	0	0.1	.	.	0	100.0
	=====		=====		=====	
	302		29		272	

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* The number of selected medications prescribed, advised over the counter, or supplied by GPs for the specific problem.



Table 7.4: 'Prescribed' regimen (All medications)\*\* by individual problem managed for each generic  
 - Allopurinol Apr05-Mar06 wgttd

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
Allopurinol	Limited function/disability NOS	1	10	mg	3	daily	0.4
	Benign/uncertain neoplasm blood/lymph	0	300	mg	1	daily	0.1
	Arthritis (excl. OA and rheumatoid)*	0	100	mg	1	daily	0.1
	Arthritis (excl. OA and rheumatoid)*	3	300	mg	1	daily	1.0
	Hypertension*	1	.	.	.	.	0.2
	Hypertension*	0	.	.	1	daily	0.2
	Hypertension*	1	200	mg	1	daily	0.2
	Hypertension*	4	300	mg	1	daily	1.2
	Hypertension*	3	300	mg	2	daily	1.0
	Preventive immun/vacc/meds-all*	1	150	mg	1	daily	0.2
	Preventive immun/vacc/meds-all*	3	300	mg	1	daily	0.9
	Prescription all*	2	.	.	.	.	0.6
	Prescription all*	4	100	mg	1	daily	1.3
	Prescription all*	3	150	mg	1	daily	0.8
	Prescription all*	1	200	mg	1	daily	0.4
	Prescription all*	23	300	mg	1	daily	7.7
	Prescription all*	0	600	mg	1	daily	0.1
	Diabetes*	2	300	mg	1	daily	0.7
	Lipid disorders*	1	100	mg	1	daily	0.4
	Chronic kidney disease*	1	150	mg	1	daily	0.2
	Limited function/disability cardiovascular	0	300	mg	1	daily	0.1
	Rheumatic fever/heart disease	1	300	mg	1	daily	0.3
	Heart failure	1	100	mg	1	daily	0.3
	Joint symptom/complaint NOS	1	100	mg	1	daily	0.2
	Gout	5	.	.	.	.	1.6
	Gout	2	.	.	1	daily	0.8
	Gout	1	50	mg	.	.	0.3
	Gout	1	50	mg	1	daily	0.3
	Gout	38	100	mg	1	daily	12.5
	Gout	3	100	mg	2	daily	1.0
Gout	3	150	mg	1	daily	1.0	
Gout	16	200	mg	1	daily	5.3	

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.4: 'Prescribed' regimen (All medications)\*\* by individual problem managed for each generic  
 - Allopurinol Apr05-Mar06 wgttd

Generic	Problem label	n meds	Dose	Units	Quantity	Frequency	% of generic group
	Gout	2	200	mg	2	daily	0.5
	Gout	0	300	mg	.		0.1
	Gout	146	300	mg	1	daily	48.6
	Gout	1	300	mg	2	daily	0.3
	Gout	1	600	mg	1	daily	0.4
	Endocrine/metabolic/nutritional disease, other	4	100	mg	1	daily	1.2
	Endocrine/metabolic/nutritional disease, other	15	300	mg	1	daily	5.0
	Haematuria	0	300	mg	1	daily	0.1
	Limited function/disability urinary	1	100	mg	1	daily	0.4
	Urinary calculus	1	100	mg	1	daily	0.3
	Urinary calculus	3	300	mg	1	daily	1.0
	Urinary disease, other	1	300	mg	1	daily	0.3
	Prostatitis/seminal vesiculitis	1	.		1	daily	0.3
	Genital disease, other (male) (incl breast)	1	300	mg	1	daily	0.3

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.

Table 7.5: 'Prescribed' daily dose (All medications)\*\* by individual problem managed for each generic  
 - Allopurinol Apr05-Mar06 wgttd

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
Allopurinol	Limited function/disability NOS	1	30	mg	0.4
	Benign/uncertain neoplasm blood/lymph	0	300	mg	0.1
	Arthritis (excl. OA and rheumatoid)*	0	100	mg	0.1
	Arthritis (excl. OA and rheumatoid)*	3	300	mg	1.1
	Hypertension*	1	200	mg	0.2
	Hypertension*	4	300	mg	1.3
	Hypertension*	3	600	mg	1.0
	Preventive immun/vacc/meds-all*	1	150	mg	0.3
	Preventive immun/vacc/meds-all*	3	300	mg	0.9
	Prescription all*	4	100	mg	1.4
	Prescription all*	3	150	mg	0.9
	Prescription all*	1	200	mg	0.4
	Prescription all*	23	300	mg	8.0
	Prescription all*	0	600	mg	0.1
	Diabetes*	2	300	mg	0.8
	Lipid disorders*	1	100	mg	0.4
	Chronic kidney disease*	1	150	mg	0.2
	Limited function/disability cardiovascular	0	300	mg	0.1
	Rheumatic fever/heart disease	1	300	mg	0.4
	Heart failure	1	100	mg	0.3
	Joint symptom/complaint NOS	1	100	mg	0.2
	Gout	1	50	mg	0.3
	Gout	38	100	mg	13.0
	Gout	3	150	mg	1.0
	Gout	19	200	mg	6.6
	Gout	146	300	mg	50.6
	Gout	2	400	mg	0.6
	Gout	2	600	mg	0.8
	Endocrine/metabolic/nutritional disease, other	4	100	mg	1.3
	Endocrine/metabolic/nutritional disease, other	15	300	mg	5.2

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 7.5: 'Prescribed' daily dose (All medications)\*\* by individual problem managed for each generic  
 - Allopurinol Apr05-Mar06 wgttd

Generic	Problem label	n meds	Prescribed daily dose**	Units	% of generic group
	Haematuria	0	300	mg	0.1
	Limited function/disability urinary	1	100	mg	0.4
	Urinary calculus	1	100	mg	0.3
	Urinary calculus	3	300	mg	1.0
	Urinary disease, other	1	300	mg	0.3
	Genital disease, other (male) (incl breast)	1	300	mg	0.3

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs.  
 The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage  
 information were recorded.

Table 7.6: Average 'prescribed' daily dose (All medications)\*\* by individual problem managed for each generic  
 - Allopurinol Apr05-Mar06 wgted

Generic	Problem label	n		Median		Minimum	Measure	Maximum	Measure	
		meds	Mean PDD	PDD	Measure					
Allopurinol	Limited function/disability NOS	1	30.0	mg	30	mg	30	mg	30	mg
	Benign/uncertain neoplasm blood/lymph	0	300.0	mg	300	mg	300	mg	300	mg
	Arthritis (excl. OA and rheumatoid)*	3	278.2	mg	300	mg	100	mg	300	mg
	Hypertension*	7	409.3	mg	300	mg	200	mg	600	mg
	Preventive immun/vacc/meds-all*	3	267.9	mg	300	mg	150	mg	300	mg
	Prescription all*	31	261.3	mg	300	mg	100	mg	600	mg
	Diabetes*	2	300.0	mg	300	mg	300	mg	300	mg
	Lipid disorders*	1	100.0	mg	100	mg	100	mg	100	mg
	Chronic kidney disease*	1	150.0	mg	150	mg	150	mg	150	mg
	Limited function/disability cardiovascular	0	300.0	mg	300	mg	300	mg	300	mg
	Rheumatic fever/heart disease	1	300.0	mg	300	mg	300	mg	300	mg
	Heart failure	1	100.0	mg	100	mg	100	mg	100	mg
	Joint symptom/complaint NOS	1	100.0	mg	100	mg	100	mg	100	mg
	Gout	211	256.0	mg	300	mg	50	mg	600	mg
	Endocrine/metabolic/nutritional disease, other	19	260.2	mg	300	mg	100	mg	300	mg
	Haematuria	0	300.0	mg	300	mg	300	mg	300	mg
	Limited function/disability urinary	1	100.0	mg	100	mg	100	mg	100	mg
	Urinary calculus	4	254.5	mg	300	mg	100	mg	300	mg
	Urinary disease, other	1	300.0	mg	300	mg	300	mg	300	mg
	Genital disease, other (male) (incl breast)	1	300.0	mg	300	mg	300	mg	300	mg

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes

See explanatory notes (Section 3) for URL where groupings are described

\*\* This table includes medications prescribed, advised for over-the-counter (OTC) purchase or supplied by GPs. The calculation of prescribed daily dose (PDD) is based on those medications for which complete regimen and dosage information were recorded.

Table 7.7: Average number of repeats by individual problem managed  
 - Allopurinol Apr05-Mar06 wgted

Problem label	n meds	Mean repeats	Median repeats	Minimum	Maximum
Gout	183	2.0	2	0	5
Prescription all*	27	2.0	2	0	5
Endocrine/metabolic/nutritional disease, other	15	2.0	2	0	5
Urinary calculus	4	1.9	2	1	5
Hypertension*	4	2.0	2	2	2
Preventive immun/vacc/meds-all*	3	1.4	2	0	2
Arthritis (excl. OA and rheumatoid)*	2	2.0	2	2	2
Limited function/disability urinary	1	2.0	2	2	2
Limited function/disability NOS	1	2.0	2	2	2
Rheumatic fever/heart disease	1	2.0	2	2	2
Heart failure	1	2.0	2	2	2
Prostatitis/seminal vesiculitis	1	0.0	0	0	0
Genital disease, other (male) (incl breast)	1	2.0	2	2	2
Diabetes*	1	5.0	5	5	5
Urinary disease, other	1	2.0	2	2	2
Chronic kidney disease*	1	0.0	0	0	0
Joint symptom/complaint NOS	1	2.0	2	2	2
Benign/uncertain neoplasm blood/lymph	0	2.0	2	2	2

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes  
 See explanatory notes (Section 3) for URL where groupings are described